The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Plain-language summary

This study examined the molecular epidemiology of EGFR mutations in patients with advanced, EGFR mutation-positive non-small cell lung cancer treated with Afatinib. It enrolled patients over 18 with metastatic, EGFR-mutated non-small cell lung cancer who received Afatinib in any line of therapy. It was a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Hellenic Cooperative Oncology Group

Intervention

Afatinib

Start date

3/15/2015

Estimated completion

5/1/2020

Related genes

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* \>18 years old
* Patients diagnosed with Non-small cell lung cancer
* metastatic disease
* Afatinib treated in any line
* EGFR mutated

Exclusion Criteria:

\-